Brief: Nature Cell receives FDA approval for early and mid-stage alzheimer's clinical trial
28/11/2016 14:00
Nov 28 (Reuters) - Nature Cell Co Ltd 007390.KQ -
* Nature Cell Co Ltd receives U.S. FDA approval for phase I
and II alzheimer's clinical trial
* Announces Astrostem's approval for phase i and phase ii
clinical trials for treatment of alzheimer's disease by U.S. FDA
on November 23
Source text for Eikon: ID:nPnXrq8Ta
Further company coverage: 007390.KQ
((bangalore.newsroom@thomsonreuters.com;))
Recent news on NatureCell
See all newsBrief: Naturecell To Conduct Capital Increase Of 5 Billion Won For Operational Funds
Brief: NatureCell To Issue 8 Million New Shares Worth 60 Billion Won
Brief: Nature Cell signs contract worth 2.54 bln won
Brief: Nature Cell signs contract worth 50.46 bln won
Brief: Nature Cell receives FDA approval for early and mid-stage alzheimer's clinical trial